Advertisement

Acta Neurologica Belgica

, Volume 117, Issue 3, pp 603–611 | Cite as

Neurological aspects of chemical and biological terrorism: guidelines for neurologists

  • Harald De Cauwer
  • Francis J. M. P. Somville
  • Marieke Joillet
Review article

Abstract

This statement paper deals with the key role an neurologist plays in the management of victims of chemical warfare/terrorist attacks. Because terrorist factions have expanded the war zone creating a worldwide risk of terrorist attacks, not only limited to some conflict zones in the Middle East, neurologists in all countries/regions have to be prepared for disaster response. The scope of this paper is to provide guidelines for the neurological management of victims of chemical and biological terrorist attacks.

Keywords

Neurology Biological warfare Chemical warfare Terrorism 

Notes

Compliance with ethical standards

Conflict of interest

All the authors report no disclosure nor conflict of interest relevant to the manuscript. All authors report no financial disclosure.

Ethical approval

This manuscript does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

None.

References

  1. 1.
    De Cauwer H, Somville F, Sabbe M, Mortelmans LJ (2017) Hospitals: soft target for terrorism? Prehospital disaster medicine. Prehosp Disaster Med 32(1):94–100CrossRefPubMedGoogle Scholar
  2. 2.
  3. 3.
    Foreign Press Center Briefing: Preview of the 2016 Nuclear Security Summit. http://www.nss2016.org/news/2016/3/30/fpc-briefing-3-29-16. Assessed 4th July 2016
  4. 4.
    Okudera H, Morita H, Iwashita T, Shibata T, Otagiri T, Kobayashi S, Yanagisawa N (1997) Unexpected nerve gas exposure in the city of Matsumoto: report of rescue activity in the first sarin gas terrorism. Am J Emerg Med 15(5):527–528CrossRefPubMedGoogle Scholar
  5. 5.
    Asai Y, Arnold JL (2003) Terrorism in Japan. Prehosp Disaster Med 18(2):106–114CrossRefPubMedGoogle Scholar
  6. 6.
    Terrorism in the United States. https://en.wikipedia.org/wiki/Terrorism_in_the_United_States. Assessed 4th July 2016
  7. 7.
    Mortelmans LJ, Van Boxstael S, De Cauwer HG, Sabbe MB (2014) Belgian Society of Emergency and Disaster Medicine (BeSEDiM) study. Preparedness of Belgian civil hospitals for chemical, biological, radiation, and nuclear incidents: are we there yet? Eur J Emerg Med 21(4):296–300CrossRefPubMedGoogle Scholar
  8. 8.
    CDC Working Group (2000) Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. MMWR Recomm Rep 49:1–14Google Scholar
  9. 9.
    Barras V, Greub G (2014) History of biological warfare and bioterrorism. Clin Microbiol Infect 20(6):497–502CrossRefPubMedGoogle Scholar
  10. 10.
    Cenciarelli O, Gabbarini V, Pietropaoli S, Malizia A, Tamburrini A, Ludovici GM et al (2015) Viral bioterrorism: Learning the lesson of Ebola virus in West Africa 2013–2015. Virus Res 210:318–326CrossRefPubMedGoogle Scholar
  11. 11.
    Bus KM, Bleck TP (2012) Treatment of neuroterrorism. Neurotherapeutics. 9(1):139–157CrossRefGoogle Scholar
  12. 12.
    Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH (1993) Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA 90(6):2291–2294CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M et al (2001) Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 7(6):933–944CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Revich BA, Podolnaya MA (2011) Thawing of permafrost may disturb historic cattle burial grounds in East Siberia. Glob Health Action. doi: 10.3402/gha.v4i0.8482 Google Scholar
  15. 15.
    Anthrax outbreak triggered by climate change kills boy in Arctic Circle. https://www.theguardian.com/world/2016/aug/01/anthrax-outbreak-climate-change-arctic-circle-russia. Assessed 31 Aug 2016
  16. 16.
    Bush LM, Abrams BH, Beall A, Johnson CC (2001) Index case of fatal inhalation anthrax due to bioterrorism in the United States. N Engl J Med 345:1607–1610CrossRefPubMedGoogle Scholar
  17. 17.
    Lanska DJ (2002) Anthrax meningoencephalitis. Neurology 59:327–334CrossRefPubMedGoogle Scholar
  18. 18.
    Kim HJ, Jun WB, Lee SH, Rho MH (2001) CT and MR findings of anthrax meningoencephalitis: report of two cases and review of the literature. AJNR Am J Neuroradiol 22:1303–1305PubMedGoogle Scholar
  19. 19.
    Sejvar JJ, Tenover FC, Stephens DS (2005) Management of anthrax meningitis. Lancet Infect Dis 5(5):287–295CrossRefPubMedGoogle Scholar
  20. 20.
    Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM et al (1999) Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281(18):1735–1745CrossRefPubMedGoogle Scholar
  21. 21.
    Dixon TC, Meselson M, Guillemin J, Hanna PC (1999) Anthrax. N Engl J Med 341:815–826CrossRefPubMedGoogle Scholar
  22. 22.
    Bower WA, Hendricks K, Pillai S, Guarnizo J, Meaney-Delman D (2015) Centers for Disease Control and Prevention (CDC). Clinical framework and medical countermeasure use during an anthrax mass-casualty incident. MMWR Recomm Rep 64(4):1–22CrossRefPubMedGoogle Scholar
  23. 23.
    Katharios-Lanwermeyer S, Holty JE, Person M, Sejvar J, Haberling D, Tubbs H et al (2016) Identifying meningitis during an anthrax mass casualty incident: systematic review of systemic anthrax since 1880. Clin Infect Dis 62(12):1537–1545CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Erbguth FJ (2004) Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord 19(Suppl 8):S2–S6CrossRefPubMedGoogle Scholar
  25. 25.
    Caya JG, Agni R, Miller JE (2004) Clostridium botulinum and the clinical laboratorian: a detailed review of botulism, including biological warfare ramifications of botulinum toxin. Arch Pathol Lab Med 128(6):653–662PubMedGoogle Scholar
  26. 26.
    Panicker JN, Muthane UB (2003) Botulinum toxins: pharmacology and its current therapeutic evidence for use. Neurol India 51(4):455–460PubMedGoogle Scholar
  27. 27.
    Franz DR, Jahrling PB, Friedlander AM et al (1997) Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278:399–411CrossRefPubMedGoogle Scholar
  28. 28.
    Martin CO, Adams HP Jr (2003) Neurological aspects of biological and chemical terrorism: a review for neurologists. Arch Neurol 60:21–25CrossRefPubMedGoogle Scholar
  29. 29.
    Arnon SS, Schechter R, Inglesby TV et al (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059–1070CrossRefPubMedGoogle Scholar
  30. 30.
    Noguchi T, Onuki K, Arakawa O (2011) Tetrodotoxin poisoning due to pufferfish and gastropods, and their intoxication mechanism. ISRN Toxicol 2011:276939CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Turner AD, Higgins C, Higman W, Hungerford J (2015) Potential threats posed by tetrodotoxins in UK waters: examination of detection methodology used in their control. Mar Drugs 13(12):7357–7376CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Food Safety Agency seeks to avert mussel scare. http://deredactie.be/cm/vrtnieuws.english/Health%2Band%2BEnvironment/1.2696432. Assessed 21 August 2016
  33. 33.
    Cole JB, Heegaard WG, Deeds JR, McGrath SC, Handy SM (2015) Centers for Disease Control and Prevention (CDC). Tetrodotoxin poisoning outbreak from imported dried puffer fish–Minneapolis, Minnesota, 2014. MMWR Morb Mortal Wkly Rep 63(51):1222–1225PubMedGoogle Scholar
  34. 34.
    Bane V, Lehane M, Dikshit M, O’Riordan A, Furey A (2014) Tetrodotoxin: chemistry, toxicity, source, distribution and detection. Toxins (Basel) 6(2):693–755CrossRefGoogle Scholar
  35. 35.
    Hajra A, Bandyopadhyay D, Hajra SK (2016) Zika virus: a global threat to humanity: a comprehensive review and current developments. N Am J Med Sci 8(3):123–128CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Centers for disease control and prevention. Transmission & risks. http://www.cdc.gov/zika/transmission/index.html. Assessed 05 Sept 2016
  37. 37.
    Broutet N, Krauer F, Riesen M, Khalakdina A, Almiron M, Aldighieri S et al (2016) Zika virus as a cause of neurologic disorders. N Engl J Med 374(16):1506–1509CrossRefPubMedGoogle Scholar
  38. 38.
    Petersen EE, Staples JE, Meaney-Delman D, Fischer M, Ellington SR, Callaghan WM et al (2016) Interim guidelines for pregnant women during a Zika virus outbreak-United States, 2016. MMWR Morb Mortal Wkly Rep 65:30–33CrossRefPubMedGoogle Scholar
  39. 39.
    Baldacchino F, Caputo B, Chandre F, Drago A, Della Torre A, Montarsi F, Rizzoli A (2015) Control methods against invasive Aedes mosquitoes in Europe: a review. Pest Manag Sci 71(11):1471–1485CrossRefPubMedGoogle Scholar
  40. 40.
    Scholte E, Den Hartog W, Dik M, Schoelitsz B, Brooks M, Schaffner F, Foussadier R, Braks M, Beeuwkes J (2010) Introduction and control of three invasive mosquito species in the Netherlands, July–October 2010. Euro Surveill 15(45)Google Scholar
  41. 41.
    Brown CM, Aranas AE, Benenson GA, Brunette G, Cetron M, Chen TH et al (2014) Centers for Disease Control and Prevention (CDC). Airport exit and entry screening for Ebola—August–November 10, 2014. MMWR Morb Mortal Wkly Rep 63(49):1163–1167PubMedGoogle Scholar
  42. 42.
    Strauss S (2014) Ebola research fueled by bioterrorism threat. CMAJ 186(16):1206CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Bray M (2003) Defense against filoviruses used as biological weapons. Antiviral Res 57(1–2):53–60CrossRefPubMedGoogle Scholar
  44. 44.
    Cenciarelli O, Gabbarini V, Pietropaoli S, Malizia A, Tamburrini A, Ludovici GM et al (2015) Viral bioterrorism: Learning the lesson of Ebola virus in West Africa 2013–2015. Virus Res 210:318–326CrossRefPubMedGoogle Scholar
  45. 45.
    Dvorin, T. (2014). Could ISIS target the West with Ebola? Arutz Sheva. IsraelNational News. http://www.israelnationalnews.com/News/News.aspx/186020#.VDvayfldWSo. Assessed 22 Aug 2016
  46. 46.
  47. 47.
    Rosello A, Mossoko M, Flasche S, Van Hoek AJ, Mbala P, Camacho A et al (2015) Ebola virus disease in the Democratic Republic of the Congo, 1976–2014. eLife 4:e09015Google Scholar
  48. 48.
    Osterholm MT, Moore KA, Kelley NS, Brosseau LM, Wong G, Murphy FA et al (2015) Transmission of Ebola viruses: what we know and what we do not know. MBio 6(2):e00137CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A et al. (2016) Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 30(388):498–503CrossRefGoogle Scholar
  50. 50.
    Howlett P, Brown C, Helderman T, Brooks T, Lisk D, Deen G, Solbrig M, Lado M, Leone S (2016) Ebola virus disease complicated by late-onset encephalitis and polyarthritis. Emerg Infect Dis 22(1):150–152CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Jacob H (1971) The neuropathology of the Marburg disease in man. In: Martini GA, Siegert R (eds) Marburg virus disease. Springer, Berlin, pp P54–P61CrossRefGoogle Scholar
  52. 52.
    Fitzgerald GJ (2008) Chemical warfare and medical response during World War I. Am J Public Health 98(4):611–625CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Moshiri M, Darchini-Maragheh E, Balali-Mood M (2012) Advances in toxicology and medical treatment of chemical warfare nerve agents. Daru 20(1):81CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Weissman BA, Raveh L (2011) Multifunctional drugs as novel antidotes for organophosphates’ poisoning. Toxicology 290(2–3):149–155CrossRefPubMedGoogle Scholar
  55. 55.
    Balali-Mood M, Balali-Mood K (2008) Neurotoxic disorders of organophosphorus compounds and their managements. Arch Iran Med 11(1):65–89PubMedGoogle Scholar
  56. 56.
    Raveh L, Eisenkraft A, Weissman BA (2014) Caramiphen edisylate: an optimal antidote against organophosphate poisoning. Toxicology 325:115–124CrossRefPubMedGoogle Scholar
  57. 57.
    Cannard K (2006) The acute treatment of nerve agent exposure. J Neurol Sci 249(1):86–94CrossRefPubMedGoogle Scholar
  58. 58.
    Mercey G, Verdelet T, Renou J, Kliachyna M, Baati R, Nachon F, Jean L, Renard PY (2012) Reactivators of acetylcholinesterase inhibited by organophosphorus nerve agents. Acc Chem Res 45(5):756–766CrossRefPubMedGoogle Scholar
  59. 59.
    Aracava Y, Pereira EF, Akkerman M, Adler M, Albuquerque EX (2009) Effectiveness of donepezil, rivastigmine, and (±)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine. J Pharmacol Exp Ther 331(3):1014–1024CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Lavon O, Eisenkraft A, Blanca M, Raveh L, Ramaty E, Krivoy A et al (2015) Is rivastigmine safe as pretreatment against nerve agents poisoning? A pharmacological, physiological and cognitive assessment in healthy young adult volunteers. Neurotoxicology 49:36–44CrossRefPubMedGoogle Scholar
  61. 61.
    Marrs TC (2004) The role of diazepam in the treatment of nerve agent poisoning in a civilian population. Toxicol Rev 23(3):145–157CrossRefPubMedGoogle Scholar
  62. 62.
    Gilat E, Kadar T, Levy A, Rabinovitz I, Cohen G, Kapon Y et al (2005) Anticonvulsant treatment of sarin-induced seizures with nasal midazolam: an electrographic, behavioral, and histological study in freely moving rats. Toxicol Appl Pharmacol 209(1):74–85CrossRefPubMedGoogle Scholar
  63. 63.
    Heffernan R, Mostashari F, Das D, Besculides M, Rodriguez C, Greenko J et al (2004) New York City syndromic surveillance systems. MMWR Suppl 53:23–27PubMedGoogle Scholar
  64. 64.
    Das D, Weiss D, Mostashari F, Treadwell T, McQuiston J, Hutwagner L et al (2003) Enhanced drop-in syndromic surveillance in New York City following September 11, 2001. J Urban Health 80(2 Suppl 1):i76–i88PubMedPubMedCentralGoogle Scholar
  65. 65.
    Donaghy M (2006) Neurologists and the threat of bioterrorism. J Neurol Sci 249:55–62CrossRefPubMedGoogle Scholar
  66. 66.
    Casebeer L, Andolsek K, Abdolrasulnia M, Green J, Weissman N, Pryor E et al (2006) Evaluation of an online bioterrorism continuing medical education course. J Contin Educ Health Prof 26(2):137–144CrossRefPubMedGoogle Scholar
  67. 67.
    Cosgrove SE, Perl TM, Song X, Sisson SD (2005) Ability of physicians to diagnose and manage illness due to category A bioterrorism agents. Arch Intern Med 165(17):2002–2006CrossRefPubMedGoogle Scholar

Copyright information

© Belgian Neurological Society 2017

Authors and Affiliations

  1. 1.Department of Neurology, Dimpna Regional HospitalAZ St DimpnaGeelBelgium
  2. 2.Department of Emergency MedicineDimpna Regional HospitalGeelBelgium
  3. 3.Department of Health PsychologyUniversity of LeidenLeidenThe Netherlands
  4. 4.Clerkships Office, Faculty of MedicineUniversity of LeuvenLouvainBelgium
  5. 5.Faculty of MedicineUniversity of MaastrichtMaastrichtThe Netherlands

Personalised recommendations